TITLE:
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

CONDITION:
Lung Cancer

INTERVENTION:
Tarceva (erlotinib HCl)

SUMMARY:

      This is a Phase IIIb, multicenter, open-label trial of daily oral Tarceva in patients with
      advanced (inoperable Stage IIIb or IV) NSCLC who have progressed following standard
      chemotherapy treatment.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Written (signed) informed consent(s)

          -  Inoperable and incurable, locally advanced, recurrent or metastatic NSCLC

          -  Relapse following standard chemotherapy (combination chemotherapy such as two-drug
             combination chemotherapy, or a single-agent chemotherapy agent for elderly or poor
             performance status patients)

          -  Age >=18 years

          -  ECOG performance status of 0 to 3

          -  Recovered from the toxic effects of prior therapy

          -  Able to comply with study and follow-up procedures

          -  Able to take oral medication

          -  Use of an effective means of contraception (for patients with reproductive potential)

          -  Granulocyte count >=1.0 x 10^9/L

          -  Platelet count >=75 x 10^9/L

          -  Serum bilirubin <1.5 x upper limit of normal (ULN)

          -  SGOT (AST) <2 x ULN unless elevation is clearly due to liver metastases; then SGOT
             (AST) must be <5 x ULN

          -  Serum creatinine <=1.5 mg/dL

        Exclusion Criteria:

          -  Any unstable systemic disease (including active infection, unstable angina,
             congestive heart failure, myocardial infarction within the last 6 months, hepatic,
             renal, or metabolic disease)

          -  Prior therapy with any systemic HER1/EGFR small molecule inhibitor, including
             gefitinib (Iressa), erlotinib (Tarceva), or other investigational agents in this
             class

          -  History of another malignancy in the past 2 years unless the malignancy has been
             adequately treated and is associated with a 5-year anticipated survival of >=90%

          -  Known central nervous system (CNS) metastases that have not yet been definitively
             treated with surgery and/or radiation or that are symptomatic or unstable

          -  Nursing mothers or pregnant females
      
